Light heavyweight Michal Oleksiejczuk has accepted a one-year suspension from USADA for failing an in-competition drug test at UFC 219 this past December.
The sanction is the same length of the one handed down by the Nevada Athletic Commission earlier this year. The NAC also fined Oleksiejczuk 30 percent of his $12,000 purse and overturned his decision victory over Khalil Rountree to a no contest.
The 23-year-old Barki, Poland, native tested positive for clomiphene, an estrogen blocker which can be used in tandem with performance enhancing drugs. Oleksiejczuk's suspension is retroactive to Dec. 30, so he will able to return at the end of 2018.
Oleksiejczuk, who was a short-notice replacement for Gokhan Saki at UFC 219, entered his Octagon debut on a nine-fight winning streak. He owns a 12-2 professional record overall.
The USADA statement is as follows:
USADA announced today that MichaÅ‚ Oleksiejczuk, of CycÃ³w, Poland, has accepted a one-year sanction for a violation of the UFC® Anti-Doping Policy after testing positive for a prohibited substance.
Oleksiejczuk, 23, tested positive for clomiphene following an in-competition urine test conducted on December 30, 2017, at UFC 219 in Las Vegas, Nev. Clomiphene is a Specified Substance in the category of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the WADA Prohibited List.
Oleksiejczuk's one-year period of ineligibility began on December 30, 2017…